- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03146689
Ibuprofen Gel or Capsaicin Cream for my Painful Knee Osteoarthritis?
Identifying Treatment Responders to a Topical Non-steroidal Anti-inflammatory Drug (NSAID) or Topical Capsaicin in Painful Knee Osteoarthritis: A Pilot Series of N-of-1 Trials
Despite evidence that topical non-steroidal anti-inflammatory drugs (NSAIDs) and capsaicin are effective in osteoarthritis (OA), it is still unclear why they work for some people but not others. The investigators are undertaking an individual patient data (IPD) meta-analysis to identify responders according to patient characteristics, however, no studies report the presence of synovial hypertrophy or neuropathic-like pain. These two traits are of interest as they may be used to optimise the treatment effects of the two drugs which work via different mechanisms to reduce pain in OA. The investigators are therefore conducting this pilot n-of-1 trial series.
This pilot n-of-1 trial series will investigate whether a person with OA, who has a different balance between inflammatory and neuropathic pain, shows a preference between these mechanistically different treatments. The trial will also be used to offer recommendations on the use of n-of-1 trial series for individualised (precision) medicine in OA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
- Academic Rheumatology, University of Nottingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Men and non-pregnant women who have had ultrasound and radiographic assessments in the Knee Pain in the Community study
o Premenopausal women will need to be on an acceptable contraceptive method
- Aged 40-95 years
- Knee pain between 4-8 on the NRS
Knee osteoarthritis - defined as knee pain plus radiographic changes, based on previous questionnaire responses and radiographic findings
- Knee pain: individuals with knee pain in and around the knee on most days for at least a month.
- Radiographic changes: definite joint space narrowing and definite osteophytes (each scoring two or more on the Nottingham Line Drawing Atlas) in the tibiofemoral and/or patellofemoral compartments
Predominantly neuropathic or inflammatory phenotypes based on previous questionnaire responses (not current status)
- Predominantly neuropathic phenotype: painDETECT Questionnaire (PDQ) > 13 and synovial hypertrophy (SH) <4 mm
- Predominantly inflammatory phenotype: SH > 4 mm and PDQ < 13
- If we cannot recruit enough people with the above thresholds, we will base recruitment on the overall distribution of PDQ and SH scores from the population. The third tertile of PDQ and the first tertile of SH for neuropathic and the first tertile of PDQ and the third tertile of SH for inflammatory phenotypes.
Exclusion Criteria:
- Inability to give informed consent
- Daily use of oral NSAIDs for the last two weeks
- Prior use of Ibuprofen gel or Zacin on the affected knee(s)
- Terminal or untreated major mental illness
- Pregnancy or breastfeeding
- Hypersensitivity or allergy to topical NSAIDs, capsaicin, or other ingredients in the preparations. This includes individuals that experience attacks of asthma, urticaria, or acute rhinitis that are precipitated by NSAIDs
- Current treatment for stomach or duodenal ulcers
- Total joint replacement of affected joint
- Renal failure
- Taking anticoagulants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical NSAID and topical capsaicin
Within each participant: Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA). This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two). |
Applied four times daily
Other Names:
Applied four times daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline knee pain on 0-10 numeric rating scale (NRS)
Time Frame: Baseline and end of each treatment period (i.e., after four weeks of treatment)
|
Pain experienced in the most painful knee in the past week will be recorded.
The following question will be asked for this purpose: "In the past week, on average, how intense was your knee pain rated on a 0-10 scale, where 0 is 'no pain' and 10 is 'pain as bad as could be'?".
The change in pain score between period baseline and period end will be calculated
|
Baseline and end of each treatment period (i.e., after four weeks of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
End-of-cycle treatment preference
Time Frame: At the end of each treatment cycle (i.e., after 4 weeks of NSAID and 4 weeks of capsaicin).
|
"Considering only the pain relief experienced in this most recent cycle, which treatment do you feel provided satisfactory pain relief?"
|
At the end of each treatment cycle (i.e., after 4 weeks of NSAID and 4 weeks of capsaicin).
|
End-of-study overall treatment preference
Time Frame: At study completion - following six treatment periods (24 weeks of treatment, excluding washouts) or 4 treatment periods for responders at the interim analysis (16 weeks of treatment, excluding washouts)
|
"Considering all the aspects of the treatment, including its effectiveness and ease of application, which treatment do you prefer?"
|
At study completion - following six treatment periods (24 weeks of treatment, excluding washouts) or 4 treatment periods for responders at the interim analysis (16 weeks of treatment, excluding washouts)
|
Weekly knee pain on 0-10 numeric rating scale (NRS)
Time Frame: At end of week 1, week 2, week 3, and week 4 of each treatment period.
|
Pain experienced in the most painful knee in the past week will be recorded.
The following question will be asked for this purpose: "In the past week, on average, how intense was your knee pain rated on a 0-10 scale, where 0 is 'no pain' and 10 is 'pain as bad as could be'?".
|
At end of week 1, week 2, week 3, and week 4 of each treatment period.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Weiya Zhang, PhD, University of Nottingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Dermatologic Agents
- Antipruritics
- Ibuprofen
- Capsaicin
Other Study ID Numbers
- B 10022017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Topical NSAID
-
LEO PharmaCompleted
-
Yonsei UniversityCompletedMyofascial Pain Syndrome of the Upper TrapeziusKorea, Republic of
-
Qassim UniversityCairo UniversityCompleted
-
Aalborg UniversityCompleted
-
Regional Hospital HolstebroCompleted
-
St. Louis UniversityWithdrawn
-
Kayseri City HospitalCompleted
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES... and other collaboratorsWithdrawnLeishmaniasis, CutaneousColombia
-
Bispebjerg HospitalLundbeck Foundation; The Danish Rheumatism Association; Team Denmark; Danish Ministry... and other collaboratorsCompletedMuscle DamageDenmark
-
Nathan Wei, MD, FACP, FACR:Medtronic - MITG; Arthritis Treatment Center, MarylandCompletedOsteoarthritis of the Knee | CoagulopathyUnited States